Skip to content
Top Globe News – Lifestyle
Author:
Medicenna Therapeutics Corp.
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
June 11, 2026
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
June 3, 2026
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
May 19, 2026
Medicenna Announces the Launch of a Marketed Public Offering of Securities
May 13, 2026
←
Previous Page
1
2